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Introduction 
R-type channels are voltage dependent calcium channel subtypes. To date, the only 
variant of the R-type calcium channel that has been isolated and cloned is the Cav2.3 
variant, encoded by the gene Cchral (Yamazaki et al., 1998). The channel was named 
"R-type" because it was initially characterized by its resistance to nifedipine (a blocker of 
L-type calcium channels), D-conotoxin GVIA (an N-type calcium channel blocker) and 
n -Aga IVA (a blocker of P/Q-type calcium channels) (Hille 2001). The Cav2.3 calcium 
channel is selectively inhibited by the peptide SNX-482, which was isolated from venom 
of the African tarantula Hysterocrates gigas (Newcomb et al., 1998). R-type calcium 
currents are typically characterized by high voltage activation and rapid kinetics of 
deactivation (Foehring et al., 2004) . Recent studies have begun to show the channel ' s 
physiological significance. Several pathophysiological states and diseases have been 
linked to abnormal R-type calcium currents. Recently Cav2.3 has been identified as a 
regulator of physiological changes following subarachnoid hemorrhage (SA V) (Ishiguro 
et al., 2005), blood insulin regulation (Jing et al., 2005), juvenile myoclonic epilepsy 
(Suzuki et al. 2004), and regulation of synaptic transmission (Cohen et al., 2004). 
Mechanisms of the channel's regulation , reasons for its association with 
pathophysiological states, and a pharmacological inhibitor that is effective at therapeutic 
doses are still being investigated. This thesis will review many of the recent findings 
about the physiological effects of R-type calcium channels, with special emphasis given 
to the possible relationship between these channels and epilepsy. It will then present 
original research regarding the effects of the novel anti-epileptic drug topiramate on R-
type calcium channels. 
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Review of Recent Findings 
Role of Cav2.3 in cerebral aneurysm and subarachnoid hemorrhage 
Survival rates following subarachnoid hemorrhage (SAH) and cerebral aneurysms hover 
around 50%. This is partially due to constriction of the cerebral arteries following SAH. 
The constricted arteries carry insufficient blood to adequately feed the brain. Ishiguro et 
al. (2005) suggested that the arterial constriction is due to an increased expression of R-
type calcium channels in the surface membrane of vascular smooth muscle cells 
following the hemorrhaging. L-type channels are thought to be the most common type of 
calcium channels in arterial myocytes and the dominant contributor to the inward Ca2+ 
current that regulates vascular tone . However , within five days following SAH, a new 
current is introduced. It was hypothesized that this was due to the increased expression of 
the Cav2.3 channel because the new current was blocked by SNX-482. The novel 
calcium channel was isolated and mRNA encoding the pore forming subunit was 
analyzed by RT-PCR. As hypothesized , the mRNA sequence matched the known 
sequence for the Cav2.3 channel. Furthermore, SNX-482 was found to dilate the arteries 
that had previously been constricted following SAH. This observation suggests that it is 
the Cav2.3 channel which directly causes vasoconstriction of the cerebral arteries. It is 
thought that following SAH, currently unknown mechanisms stimulate the expression of 
Cav2.3 channels in the damaged blood vessels. 
Role of Cav2.3 in glucose regulation: insulin and glucagon secretion 
Pancreatic beta cells secrete insulin, which regulates blood glucose levels. Insulin is 
typically released in two phases: the first phase has a rapid onset and is transient; the 
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second phase has a slower onset and is prolonged. Type II diabetes is characterized by a 
single rapid phase insulin release, in which the longer second phase is absent. Insulin 
exocytosis is stimulated by the opening of voltage-gated calcium channels, increasing the 
intracellular Ca2+ concentration. It is believed that L-type calcium channels (specifically 
Cav 1.3) regulate the first phase of insulin release. However, knockout mice lacking 
Cav2.3 show symptoms of type II diabetes (Matsuda et al., 2001 ). Jing et al. (2005) noted 
a 21 % decrease in insulin exocytosis from beta cells of the Cav2.3 knockout mice 
compared with control mice . To assess the role of Cav2.3 in dynamic insulin release , they 
performed in situ pancreatic perforations. There was little difference between the 
knockout mice and the control mice during the initial phase of insulin release. However, 
following the initial insulin peak, insulin exocytosis dropped in the knockout mice but not 
in the control mice. This led the team to conclude that Cav2.3 is a key regulator in second 
phase insulin release. 
Pereverzev et al. (2005) showed that Cav2.3 also has minor involvement in glucagon 
secretion. Glucagon release was slightly impaired in Cav2.3 -/- knockout mice compared 
to wild-type mice . Their experiments showed a greater inhibition of glucagon release in 
vitro than in vivo. They hypothesize that Ca 2+ influx through Cav2.3 stimulates glucagon 
release. 
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The effects of µ-opioid receptors on Cav2.3 
Morphine is suspected to produce analgesic effects by inhibiting voltage-gated calcium 
channels of primary afferent neurons, and thus reducing nociceptive neurotransmitter 
release. Yokoyama et al. (2004) suggested that Cav2 .3 is immune to morphine effects , 
and that an increase of Cav2 .3 channels is directly linked to morphine tolerance . Results 
of their experiments showed that Cav2.3 -/- mice have greater resistance to developing 
morphine tolerance, as shown by response to painful stimuli during extended morphine 
treatment. They suggested that morphine tolerance might be linked to an increase in 
Cav2.3 channels following exposure. Furthermore, they found that blocking the Cav2.3 
channel alone could prevent morphine tolerance. They hypothesized that Cav2.3 interacts 
either directly or indirectly with DAG , a receptor that is thought to be the one of the 
primary targets of morphine. Studies showing this relationship have not been completed . 
The ability to inhibit morphine tolerance would reduce the amount of morphine required 
for pain treatment and allow for extended morphine treatments (Yokoyama et al., 2004) . 
In a separate study, the same group also found Cav2.3 -/- mice to have reduced sensitivity 
to anesthetics such as halothane (Takei et al., 2003). 
Ortiz-Miranda et al. (2005) showed that a µ-opioid receptor agonist called DAMGO (D-
ALA2 , MePhe4 , Glyol(S)enkephalin) inhibits oxytocin release from neurohypophysial 
cells. It had previously been established that Cav2.3 regulates oxytocin secretion, and 
they hypothesized that DAMGO preferentially blocks the Cav2.3 channel. Experiments 
in which cells were treated with both SNX- 482 and DAMGO showed that the two agents 
were not additive, suggesting that both compete for the same target, presumably the 
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Cav2.3 channel. After isolating R-type calcium currents , they were able to show that 
DAM GO selectively inhibited the current. They believe that the blocking of Cav2.3 
channels by µ-opioid receptors may be a general mechanism of opiates (Ortiz-Miranda et 
al., 2005). 
The potential role of Cav2.3 in epilepsy 
Cav2.3 has been recently implicated in epilepsy. Suzuki et al. (2004) recently identified 
the EFHCl gene. This gene is thought to encode protein containing an E-F hand motif. 
EFHCl appears to be very closely linked to a Cav2.3 channel. When the EFHCl protein 
was precipitated with an antibody , the Cav2.3 channel precipitated with it. Mutations in 
the EFHC 1 gene were found in several different cases of juvenile myoclonic epilepsy in 
unrelated families. Apoptosis increased when cells that naturally express Cav2.3 were 
transfected with EFHC 1. Conversely , cell survival rates increased when cells expressing 
both EFHCl and Cav2 .3 were administer ed the R-type blocker SNX-48 2. No differenc e 
in apoptosis rate was observed when the cells were treated with agents that block Cav2 . l 
and Cav2.2 . The team hypothesized that EFHCl increases Ca 2+ flow through Cav2.3 
channels and stimulates apoptosis in developing nervous systems. Neurons with a mutant 
form of EFHCl fail to stimulate sufficient Ca 2+ influx through Cav2 .3; this prevents 
normal apoptosis , leading to excess neurons. Excess neurons are thought to be unstable 
and fire spontaneously, possibly leading to grand ma! episodes. However, the mechanism 
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by which EFHC 1 causes epilepsy is not fully understood. Its association with epilepsy 
could be the result of downstream targets other than Cav2.3. Interestingly, epilepsy has 
not been observed in Cav2.3 -/- mice. The team hypothesized that this could be due to 
insufficient observation , or species-independent responses. 
Kuzmiski et al. (2005) suggested another possible relationship between Cav2.3 and 
epilepsy. They observed that the anti-epileptic drug topiramate depressed plateau 
potentials in hippocampal CA 1 pyramidal neurons by an unknown mechanism. Plateau 
potentials are thought to contribute to epileptic activity in the hippocampus. After 
treatment with a series of channel blocking agents , including O-conotoxin MVIIC , O-
conotoxin GVIA, and O-agatoxin, they attributed the depression to a topiramate-induced 
reduction of blocker-resistant calcium currents. To follow up this experiment , they 
transfected Cav2.3 into tsA-201 Human Embryonic Kidney Cells , a cell line that 
normall y does not express high voltage-activated calcium channels . In this cell line, they 
once again showed that topiramate blocked the calcium current. 
They continued to hypothesize that flow through R-type calcium channels accounts for 
about 80% of the current required to achieve the plateau potential. They attributed the 
remaining 20% to low-voltage activated T-type calcium channels , which are also resistant 
to traditional calcium channel blockers , and to other unknown mechanisms. It is 
suggested that the development of agents that block Cav2.3 currents at therapeutic 
concentrations may be used as a way of treating epilepsy (Kuzmiski et al., 2005). 
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Original Research to Investigate the Effects of Topiramate on Cav2.3 
Introduction 
Topiramate is a novel antiepileptic drug that has also been found effective against 
migraines, bulimia, bipolar disorder, and post-traumatic stress disorder (Russo et al., 
2004). It has been shown to have an antiepileptic effect in 40-50% of people who take it. 
Those benefited by the drug have a 50 % reduction in partial seizures and an 89-100% 
reduction in tonic-clonic seizures. Side effects include cognitive difficulties, ataxia, 
dizziness, headaches, fatigue, gastrointestinal upset, and renal calculi. Topiramate is 
known to block sodium channels and inhibit y-aminobutyric acid receptors, induce 
cytochrome P450, and attenuate kainate-induced responses. However, the exact 
mechanisms of topiramate remain unknown (Dichter et al., 1996). Thapliyal et al. 
(unpublished results) showed that topiramate leads to a 15% reduction of Cav2.3 Ca2+ 
current in HEK 293 cells. Fraser and Mac Vicar (1996) suggested that the muscarinic 
agonist carbachol induces epilepsy-like plateau potentials in hippocampal neurons. 
Interestingly Kuzmiski et al. (2005) showed that these plateau potentials were partially 
caused by Cav2.3 and were blocked by topiramate. In Melliti et al., (2000) it was shown 
that carbachol can lead to stimulation of Cav2.3. Therefore, we sought to investigate 
whether topiramate blocks Ca2+ current through Cav2.3 by preventing the muscarinic-




Human Embryonic Kidney 293 (HEK293) cells were obtained from American Type 
Culture Collection. They were cultured in 90% Dulbecco Modified Eagle Medium 11995 
(Gibco) with 10% Fetal Bovine Serum (Hyclone Labs, Logan, Utah) and 50 µg/ml 
gentamicin (Gibco ). Cultures were incubated at 37° Celsius in a water-saturated 
atmosphere containing 5% CO2. The cells were passaged weekly by being trypsinized for 
30 seconds and replated on to culture dishes. 
Transfection 
Cells were transfected using CaPO4 precipitation between 12 and 24 hours after plating 
with plasmids encoding Cav2.3 (GenBank accession number X67856) , a2o (M86621) , 133 
(X64300). Cells were also transfected with plasmids encoding enhanced green 
fluorescence protein (EGFP) . In addition , the cells were transfected with either the 
acetylcholine Ml muscarinic receptor (MIR) or Neurokinin 1 receptor (NKlR) 
(NM0 15727). 
Electrophysiological recordings 
Large-bore patch pipettes were pulled from 100 µl borosilicate glass micropipettes 
(VWR). The pipette resistance was between 1 and 4 Mn. Pipettes were filled with a 
solution containing 155 mM CsCl , 10 mM Cs2EGTA, 4mM MgATP, 0.32 mM LiGTP , 
and 10 mM HEPES brought to a pH of 7.4 using CsOH. Aliquots of the pipette solution 
were stored at -80° Celsius. 
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The bath solution contained 145 mM NaCl, 10 mM CaC'2, 2 mM KCI, and 10 mM 
HEPES. The pH of the bath solution was brought to 7.4 with 1 N NaOH. 
Transfected cells were identified by the presence of green fluorescence when stimulated 
by 488 nm wavelength light and by the presence of voltage-dependent calcium current. 
Data were only recorded from cells meeting both of these criteria. Patch recordings were 
generated using the protocol described in Melliti et al. (2000). Data were collected using 
the whole -cell ruptured-patch technique with seal of greater than one GO. The steady 
holding potential was - 90 mV. Depolarizations to +30 mV were delivered every 1-10 
seconds. Data were recorded using an Axopatch 200B amplifier (Axon Instruments, 
Foster City, CA) and pCLAMP 7.0 software (Axon Instruments) 
Results 
Recordings from cells transfected with Cav2.3 , a28, B3, and NKlR were taken in the 
whole-cell ruptured-patch configuration. Cells were held at -90 m V and stimulated every 
1-10 seconds. The results of this experiment can be seen in Figure 1. 
+20 mV 
-90 mV -90 mV 
SOOpAL 
5 ms 
Figure I : A representative Ca2+ current from a HEK293 cell expressing Cav2.3. Tail 
current has been removed for presentation. 
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The effect of the drug topiramate was determined by using HEK cells transfected with 
Cav2.3, a20, /33, Ml, and EGFP. Cells were incubated with 50 µM topiramate (in media 
containing 0.1 % DMSO) for 1-3 hours before patching. The bath solutions also contained 
50 µM topiramate and 0.1 % DMSO. Cells were stimulated with 1 mM carbachol for 1 
minute before being washed out. Control cells were exposed to the same concentration of 
11 !""'m_"""""la.>L7"-=......,._~ ........ 
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Figure 2: Peak Cav2. 3 currents of cells treated with topiramate and then exposed to CCh 
for ~2 minutes. Both the topiramate-treated cell (A) and the control cell (B, not treated 
with topiramate) show both inhibition and stimulation of Cav2.3 current when subjected 
toCCH 
DMSO without topiramate. These data are preliminary; not enough data have been 
collected to make statistically valid statements about the overall effect of topiramate on 
Cav2.3 via MIR. However , topiramate failed to consistently block carbachol-induced 
stimulation of Cav2.3 current. It is possible that topiramate reduces channel activation , 
without blocking it directly. The results of these experiments can be seen in Figure 2. 
Discussion 
Recent studies have shown that R-type calcium currents play key roles in several 
neurological disorders, including epilepsy. Kuzmiski et al., (2005) showed that Cav2.3 is 
involved in the generation of hippocampal plateau potentials, and that Cav2.3 is one of 
the targets of topiramate . Although our data fail to show that topiramate consistently 
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block stimulation of Cav2 .3 through MIR, topiramate might reduce stimulation . 
However , topiramate might also reduce calcium current and block plateau potentials 
through another mechanism; possibly topiramate simply blocks the pore-forming subunit 
of Cav2.3. Metz et al. (2005) showed that R-type calcium currents responsible for 
epilepsy-like after-depolarizations are resistant to SNX-482, suggesting that additional R-
type calcium channel isoforms might be involved. At this point, the data are preliminary, 
and it is difficult to make sound conclusions. Future experiments will seek to further 
establish the relationship between topiramate and Cav2.3. A possible experiment could 
involve transfection with a single plasmid encoding Cav2.3, a28, 133, and Ml. This might 
enable more control over the relative amount of each subunit expressed in the cell. Also , 
lower concentrations of carbachol could be used to stimulate the channel without 
inhibiting it, thus simplifying the results and removing compounding factors . 
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